---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-052377"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:19:38.260849+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# BiomX posts updated corporate presentation; no material new disclosures

## Summary
- Posted updated slide deck in Investors section of website on June 9, 2025.
- Presentation titled 'Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance'.
- No specific financial data, guidance changes, or clinical milestones disclosed in the filing.
- Filed under Regulation FD; company undertakes no obligation to update the materials.

## SEC filing metadata
- accession: 0001213900-25-052377
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/0001213900-25-052377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/ea0245109-8k_biomxinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-052377
- JSON: https://secwatch.observer/filing/0001213900-25-052377.json
- Plain text: https://secwatch.observer/filing/0001213900-25-052377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.